Research Paper Volume 15, Issue 5 pp 1445—1474
Identification of GNG7 as a novel biomarker and potential therapeutic target for gastric cancer via bioinformatic analysis and in vitro experiments
Figure 7. Expression patterns of GNG7 in GC analyzed using bioinformatics tools. (A) The expression of GNG7 in multiple human cancers was visualized using the TIMER database. (B) Expression of GNG7 in different human cancers was revealed using the Oncomine database. P < 1E-4 and |log2FC| > 2 were utilized as the statistic threshold. (C) Expression of GNG7 in multiple human cancers was analyzed via the GEPIA web tool. (D–F) Expression levels of GNG7 in GC and normal samples were derived from the GSE13861, GSE13911, and GSE19826 datasets. (G) Expression of GNG7 in STAD was detected using the UALCAN database. AML, acute myelogenous leukemia; FC, fold change; GC, gastric cancer; GEPIA, Gene Expression Profiling Interactive Analysis; STAD, stomach adenocarcinoma; and TIMER, Tumor Immune Estimation Resource. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control.